Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 8/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 1/20 | 0.44 |
| ▸ | FNTB | P49356 | 1/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.42 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CASP2 | P42575 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.42 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25305503 | 1.00 | NOD1 (0.51) | NOD1EPHX1GPR84FFAR1FNTA | |
| SCHEMBL11423050 | 1.00 | NOD1 (0.51) | NOD1EPHX1GPR84FFAR1FNTA | |
| SCHEMBL19750215 | 1.00 | NOD1 (0.51) | NOD1EPHX1GPR84FFAR1FNTA | |
| SCHEMBL25244993 | 1.00 | NOD1 (0.51) | NOD1EPHX1GPR84FFAR1FNTA | |
| SCHEMBL7081523 | 1.00 | NOD1 (0.51) | NOD1EPHX1GPR84FFAR1FNTA | |
| SCHEMBL5309803 | 0.98 | NOD1 (0.49) | NOD1EPHX1GPR84FFAR1FNTA | |
| SCHEMBL24660133 | 0.86 | NOD1 (0.50) | NOD1EPHX1GPR84FFAR1FNTA | |
| SCHEMBL7568502 | 0.86 | NOD1 (0.61) | NOD1EPHX1GPR84FFAR1FNTA | |
| SCHEMBL25253112 | 0.86 | NOD1 (0.50) | NOD1EPHX1GPR84FFAR1FNTA | |
| SCHEMBL17080400 | 0.86 | NOD1 (0.61) | NOD1EPHX1GPR84FFAR1FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118632867-A | GLP-1/GIP receptor co-agonist prodrugs and uses thereof | 诺和诺德股份有限公司 | 2024-09-10 | — | — | CN | claimed |
| EP-4466069-A1 | GLP-1/GIP RECEPTOR CO-AGONIST PRODRUGS AND USES THEREOF | Novo Nordisk A/S (DK) | 2024-11-27 | — | — | EP | disclosed |
| CN-118632867-A | GLP-1/GIP receptor co-agonist prodrugs and uses thereof | 诺和诺德股份有限公司 | 2024-09-10 | — | — | CN | disclosed |
| US-20240083965-A1 | PRODRUGS AND USES THEREOF | NOVO NORDISK AS (DK) | 2024-03-14 | — | — | US | disclosed |
| US-11840560-B2 | Prodrugs and uses thereof | NOVO NORDISK A/S (DK) | 2023-12-12 | — | — | US | disclosed |
| US-11840560-B2 | Prodrugs and uses thereof | NOVO NORDISK A/S (DK) | 2023-12-12 | — | — | US | disclosed |
| US-11840560-B2 | Prodrugs and uses thereof | NOVO NORDISK A/S (DK) | 2023-12-12 | — | — | US | disclosed |
| WO-2023139187-A1 | GLP-1/GIP RECEPTOR CO-AGONIST PRODRUGS AND USES THEREOF | NOVO NORDISK A/S (DK) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023139187-A1 | GLP-1/GIP RECEPTOR CO-AGONIST PRODRUGS AND USES THEREOF | NOVO NORDISK A/S (DK) | 2023-07-27 | — | — | WO | disclosed |
| US-20230227521-A1 | PRODRUGS AND USES THEREOF | NOVO NORDISK A/S (DK) | 2023-07-20 | — | — | US | disclosed |
| US-20230227521-A1 | PRODRUGS AND USES THEREOF | NOVO NORDISK A/S (DK) | 2023-07-20 | — | — | US | disclosed |
| US-20230227521-A1 | PRODRUGS AND USES THEREOF | NOVO NORDISK A/S (DK) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840560-B2 | Prodrugs and uses thereof | GIPR, GLP1R, GRPR | NOD1 687/4885EPHX1 2957/4885GPR84 69/4885 |
| US-20230227521-A1 | PRODRUGS AND USES THEREOF | GIPR, GLP1R, GRPR | NOD1 687/4885EPHX1 2957/4885GPR84 69/4885 |
| US-20240083965-A1 | PRODRUGS AND USES THEREOF | GIPR, GLP1R, GRPR | NOD1 687/4885EPHX1 2957/4885GPR84 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.